Which laboratory tests should be obtained before initiating testosterone therapy in a male patient, and how should the results be interpreted?

Laboratory Testing for Testosterone Therapy: Essential Pre-Treatment and Monitoring Protocol

Before prescribing testosterone, obtain two fasting morning (7-10 AM) total testosterone levels showing values <264-300 ng/dL, plus hematocrit, PSA (if age ≥40 and baseline PSA >0.6 ng/ml), and LH/FSH to distinguish primary from secondary hypogonadism. 1

Baseline Laboratory Requirements

Core Pre-Treatment Labs

Total Testosterone:

• Measure on two separate mornings between 7-10 AM in fasting state 1
• Must be <264-300 ng/dL (varies by guideline; Endocrine Society uses <300 ng/dL threshold) 2, 3
• Use an accurate, externally quality-controlled assay 2

Free or Calculated Free Testosterone:

• Required for men with obesity, diabetes, or conditions causing low SHBG 2, 4
• Calculate using total testosterone and SHBG concentrations 2

Gonadotropins (LH and FSH):

• Mandatory to distinguish primary (elevated LH/FSH) from secondary (low or inappropriately normal LH/FSH) hypogonadism 1, 2
• This distinction determines whether the problem is testicular or hypothalamic-pituitary 2

Hematocrit:

• Baseline measurement required 1
• Hematocrit >50% is a relative contraindication - these men need further evaluation before considering therapy 1
• Hematocrit >54% is an absolute contraindication until it decreases 1

Prostate Monitoring (Age-Dependent):

• For men ≥40 years with baseline PSA >0.6 ng/ml: perform digital rectal examination (DRE) and check PSA before treatment 1
• Younger men or those with PSA ≤0.6 ng/ml: follow age-appropriate screening guidelines 1

Metabolic Panel:

• Glucose and lipid profile 5

Interpretation Algorithm

Step 1: Confirm Hypogonadism

• Both symptoms (decreased libido, erectile dysfunction, fatigue) AND two morning testosterone values <300 ng/dL required 1, 2, 3
• Symptoms alone or single low value insufficient for diagnosis 2, 4

Step 2: Classify Type

• Primary hypogonadism: Low testosterone + elevated LH/FSH (testicular failure, e.g., Klinefelter syndrome) 2
• Secondary hypogonadism: Low testosterone + low or inappropriately normal LH/FSH (hypothalamic-pituitary dysfunction) 2

Step 3: Identify Reversible Causes (Secondary Hypogonadism)

Before initiating testosterone, address:

• Obesity (BMI ≥30): Weight loss ≥5% typically increases testosterone and improves symptoms - this is first-line therapy 2, 3, 6
• Medications: Opioids, corticosteroids, checkpoint inhibitors, drugs causing hyperprolactinemia 2
• Severe illness 2

Step 4: Screen for Contraindications

Absolute contraindications:

• Prostate or breast cancer 7, 4, 6
• Hematocrit >54% 1
• Recent major cardiovascular event 4
• Uncontrolled heart failure 4, 6
• Severe untreated sleep apnea 4

Relative contraindications:

• Hematocrit 50-54% 1
• Severe lower urinary tract symptoms (AUA/IPSS >19) without urologic evaluation 1, 6
• Increased prostate cancer risk without prior evaluation 4

Monitoring Protocol After Initiation

At 3-6 Months:

Testosterone Level:

• Timing depends on formulation 1:
  • Injectable (enanthate/cypionate): Midway between injections; adjust if >700 ng/dL or <400 ng/dL 1
  • Transdermal gels: Any time after ≥1 week of treatment 1
  • Patches: 3-12 hours after application 1
• Target: Mid-normal range (approximately 400-700 ng/dL) 1

Hematocrit:

• Check at 3-6 months 1
• If >54%: Stop therapy immediately, evaluate for hypoxia/sleep apnea, restart at reduced dose only after hematocrit decreases 1

PSA (if applicable):

• Men ≥40 years with baseline PSA >0.6 ng/ml: recheck at 3-6 months 1

Symptom Assessment:

• Evaluate whether symptoms have responded to treatment 1

Annual Monitoring:

• Hematocrit annually 1
• Testosterone level to confirm mid-normal range 1
• PSA and DRE per age-appropriate screening guidelines 1
• Clinical assessment of symptom response and adverse effects 1

Critical Red Flags Requiring Urologic Referral

Stop and refer immediately if:

• PSA increase >1.4 ng/ml within any 12-month period 1
• PSA velocity >0.4 ng/ml/year (using 6-month value as reference, requires >2 years data) 1
• Abnormal DRE findings 1
• AUA/IPSS score >19 1
• Verified PSA >4.0 ng/ml 8

Common Pitfalls to Avoid

1. Single testosterone measurement: Always confirm with two separate morning samples 1, 2
2. Afternoon testing: Testosterone has diurnal variation; only morning (7-10 AM) values are valid 1, 2
3. Ignoring SHBG: In obese/diabetic men, total testosterone may be misleadingly low due to low SHBG - calculate free testosterone 2, 4
4. Skipping gonadotropins: Cannot distinguish primary from secondary hypogonadism without LH/FSH 2
5. Missing reversible causes: Obesity-induced hypogonadism requires weight loss first, not testosterone 2, 3, 6
6. Inadequate hematocrit monitoring: Polycythemia is dose-dependent and more common in older men - this can cause thrombotic events 1, 7
7. Wrong timing for injectable monitoring: Must measure midway between injections, not at trough or peak 1, 9

The evidence strongly supports that testosterone therapy should only be initiated after confirming both biochemical hypogonadism (two low morning values) and compatible symptoms, with mandatory exclusion of reversible causes and contraindications 1, 2, 4, 6.